A5101525790- Inflammatory Bowel Disease
- Microscopic Colitis
- Eosinophilic Esophagitis
- Pregnancy and Medication Impact
- Biosimilars and Bioanalytical Methods
- Immunodeficiency and Autoimmune Disorders
- Health Systems, Economic Evaluations, Quality of Life
- Colorectal Cancer Screening and Detection
- Reproductive System and Pregnancy
- Liver Diseases and Immunity
- Colorectal Cancer Treatments and Studies
- SARS-CoV-2 and COVID-19 Research
- Clostridium difficile and Clostridium perfringens research
- Colorectal Cancer Surgical Treatments
- Immune Cell Function and Interaction
- DNA Repair Mechanisms
- Chronic Lymphocytic Leukemia Research
- Adolescent and Pediatric Healthcare
- T-cell and B-cell Immunology
- IL-33, ST2, and ILC Pathways
- Genetic factors in colorectal cancer
- Child and Adolescent Health
- Autoimmune and Inflammatory Disorders Research
- Cancer, Lipids, and Metabolism
- Appendicitis Diagnosis and Management
St. Vincent's University Hospital
2012-2025
University College Dublin
2010-2025
Cancer Trials Ireland
2018-2020
Beaumont Hospital
2010
Summary Background Women with inflammatory bowel diseases (IBD) often receive biologicals during pregnancy to maintain disease remission. Data on outcome of vedolizumab‐exposed pregnancies (VDZE) are sparse. Aims To assess and child outcomes VDZE compare these results anti‐TNF exposed (TNFE) or both immunomodulatory biologic unexposed (CON IBD) pregnancies. Methods A retrospective multicentre case‐control observational study was performed. Results group included 79 in 73 IBD women. The TNFE...
Identifying hospitalized patients with acute severe ulcerative colitis (ASUC) who will be refractory to corticosteroid therapy and require rescue remains difficult. Hypoalbuminemia worsens time during hospitalization is associated rapid clearance of reduced response infliximab (IFX) rescue. Early use may therefore more effective. Simple clinical laboratory predictors responsiveness would facilitate earlier therapy.Retrospective study a prospectively maintained database 3600 attending single...
A 35-year old woman with ileocolonic, perianal, and vulval Crohn's disease was treated subcutaneous ustekinuamb [USK] throughout pregnancy. Dose intervals were shortened from 6-weekly to 4-weekly maintain clinical remission. The last dose of USK administered at 33 weeks gestation, a healthy baby boy delivered by caesarean section 37 weeks. Maternal trough levels remained stable during Cord blood nearly 2-fold higher than contemporaneous maternal serum levels. To our knowledge, this is the...
Evidence suggests patients with inflammatory bowel disease [IBD] receiving TNF antagonists have attenuated response to vaccination against COVID-19. We sought determine the impact of IBD and various medications for treatment on antibody responses Patients [n = 270] healthy controls [HC, n 116] were recruited prospectively, quantitative assessed following COVID-19 vaccination. The vaccine rates was investigated. Of HC, 100% seroconverted complete two doses; 2% failed seroconvert. Median...
Abstract Background Ustekinumab (UST) is an anti-IL12/23 monoclonal antibody approved for use in psoriasis and inflammatory bowel disease (IBD). HLA-C*06 allele carriage has been associated with higher rates of response to UST patient populations.1 The association between IBD not previously evaluated. We aimed further explore as a pharmacogenetic marker therapy patients. Methods A multi-centre retrospective study patients treated Ireland was performed. Baseline demographics the cohort were...
Abstract Background The National Bowel Screening Program (Bowelscreen), a nationwide initiative program, aims to provide direct access those aged 55-74 (currently 59-69) for colonoscopy assessment deemed high risk colorectal cancer via positive faecal immunochemical test (FIT). Inflammatory Disease (IBD) follows bimodal distribution of onset with European studies reporting 10-15% diagnosis after age 60. Limited published research exists on IBD incidence in Ireland FIT-based population...
Abstract Background Sustainability of IBD care has been identified as a key priority for the coming years by ECCO part REACH strategy. Additionally, Irish Health Service Climate Action Strategy aims to achieve net-zero emissions 2050 and provide healthcare that is environmentally socially sustainable. The STRIDE II consensus discusses new treatment goals in such endoscopic healing which would require more frequent monitoring. However this poses an environmental burden one MRI generates...
Oxidative DNA damage results from adducts such as 8-oxo-7, 8 dihydro-2'-deoxyguanosine (8-oxo-dG), which is a pro-mutagenic lesion. No known association between 8-oxo-dG, disease progression and survival exists in colorectal cancer (CRC). We examined levels of 8-oxo-dG sporadic CRC to determine its relationship with pathological stage outcome. A total 143 patients 105 non-cancer were studied. Nuclear cytoplasmic was assessed using immunohistochemistry. Double immunofluorescence manganese...
Endoscopic scores of local severity do not reflect disease extent, or burden. The DUBLIN score is a simple bedside clinical that estimates inflammatory burden using both and extent. As the need to personalize therapy for ulcerative colitis [UC] patients increases, accurately assessing will be great relevance. aim this study was assess utility by comparing its performance with objective biomarkers.The calculated as product Mayo Score [0-3] extent [E1-E3]. Correlation biomarkers performed in...
Recent studies report an increased risk of non-melanoma skin cancer (NMSC) in immunosuppressed patients with inflammatory bowel disease (IBD). Concurrently, paediatric IBD incidence is rising, more now exposed to immunomodulators from a younger age.To investigate NMSC and examine the associated development IBD.This was retrospective single-centre cohort study. Patients attending tertiary adult hospital 1994 2013 were included. Skin compared population data National Cancer Registry Ireland...
Summary Background Ustekinumab ( USK ) is licenced for intravenous induction and subcutaneous (S/C) maintenance in Crohn's disease. Aim To evaluate ustekinumab trough concentrations clinical response with exclusive induction. Methods Patients disease who initiated treatment at a single academic centre were included this pilot study. A dosage of 360 mg was given subcutaneously divided doses; 180 Week 0, 90 1 2, corresponding assessed to 8. The primary outcome measures serum levels remission...
A number of epidemiological studies suggest that the consumption green tea reduces incidence prostate cancer. As major catechins present in are potent antioxidants, we hypothesized genetic and cellular damage induced by oxygen free radicals could be significantly reduced antioxidants tea, thus reducing cumulative with age, slowing or preventing tumour formation. Long-term administration a decaffeinated extract to Lobund–Wistar rats for periods up 26 months almost halved primary tumours...
Patients with inflammatory bowel disease [IBD] have an attenuated response to initial COVID-19 vaccination. We sought characterize the impact of IBD and its treatment on responses after third vaccine against SARS-CoV-2.This was a prospective multicentre observational study patients [n = 202] healthy controls [HC, n 92]. Serological vaccination assessed by quantification anti-spike protein [SP] immunoglobulin [Ig]G levels [anti-SPIgG] in vitro neutralization binding angiotensin-converting...
Introduction Ulcerative colitis (UC) is a chronic inflammatory bowel disease (IBD), often leading to an impaired quality of life in affected patients. Current treatment modalities include antitumour necrosis factor (anti-TNF) monoclonal antibodies (mABs) including infliximab, adalimumab and golimumab (GLM). Several recent retrospective prospective studies have demonstrated that fixed dosing schedules anti-TNF agents fails consistently achieve adequate circulating therapeutic drug levels (DL)...
Background and aims Golimumab (GLB) is an antitumour necrosis factor-α (anti-TNF) therapy that has shown efficacy as induction maintenance for ulcerative colitis (UC). We aimed to describe the outcome of GLB UC in a real-world clinical practice. Patients methods Consecutive patients receiving six Irish Academic Medical Centres were identified. The primary study endpoint was 6-month corticosteroid-free remission rate. secondary endpoints included 3-month response, time free discontinuation...
Accelerated dose infliximab (IFX) induction is associated with reduced short-term colectomy rate in acute severe ulcerative colitis (ASUC). Data on medium/long-term outcomes of this strategy are limited.Evaluate patients receiving IFX for ASUC, comparing accelerated (AD) and standard (SD) induction.Retrospective study consecutive admitted corticosteroid-refractory ASUC four tertiary referral centres within INITIative IBD research network (www.initiativeibd.ie). rescue was given either as SD...
Objective The Inflammatory Bowel Disease Disability Index (IBD-DI) was developed according to WHO standards and has been validated in population-based cohorts. However, there are limited data on its relationship various psychosocial economic variables or relevance hospital clinical practice. study aims were determine the validity reliability of IBD-DI an English-speaking out-patient population evaluate association with short long-term disease activity. Design/Methods 329 subjects enrolled a...
Women with inflammatory bowel diseases (IBD) often receive biologicals during pregnancy to maintain disease remission prior conception and throughout pregnancy. However, data on vedolizumab exposed pregnancies (VDZE) are scarce. This retrospective multi-centre observational study assessed outcomes of VDZE in IBD patients (group A). European gastroenterologists were asked report all pregnancies. Details underlying IBD, pre- postnatal collected. Results compared anti-TNF (TNFE, group B) or...